35.[20220924]Transplantation in the Age of Precision Medicine_Treg Tx
페이지 정보
작성자 신호식 작성일23-02-03 13:29 조회426회 댓글0건관련링크
-
https://youtu.be/PvhMKdvp34o
438회 연결
https://youtu.be/PvhMKdvp34o
본문
첨부한 자료(유튜브 클립, 참고문헌 등)를 학문적 목적으로만 사용해 주시길 부탁드립니다
Review Semin Nephrol
. 2022 Jan;42(1):76-85. doi: 10.1016/j.semnephrol.2022.01.002.
Transplantation in the Age of Precision Medicine: The Emerging Field of Treg Therapy
Charles G Rickert 1, James F Markmann 2
Affiliations expand
PMID: 35618397 DOI: 10.1016/j.semnephrol.2022.01.002
Abstract
Solid organ transplantation has experienced incredible success over the past half century in rescuing patients with end-stage organ failure and bestowing them with a high quality of life. This success in large part is the result of advances in immunosuppression, however, these regimens come with significant costs including opportunistic infections, and in some cases, direct toxicity to the newly transplanted organs. Further advances are needed. Immunosuppression and tolerance based on regulatory T cells provide an attractive alternative because of their ability to target these immunomodulatory functions specifically to the anti-allograft immune response.
Review Semin Nephrol
. 2022 Jan;42(1):76-85. doi: 10.1016/j.semnephrol.2022.01.002.
Transplantation in the Age of Precision Medicine: The Emerging Field of Treg Therapy
Charles G Rickert 1, James F Markmann 2
Affiliations expand
PMID: 35618397 DOI: 10.1016/j.semnephrol.2022.01.002
Abstract
Solid organ transplantation has experienced incredible success over the past half century in rescuing patients with end-stage organ failure and bestowing them with a high quality of life. This success in large part is the result of advances in immunosuppression, however, these regimens come with significant costs including opportunistic infections, and in some cases, direct toxicity to the newly transplanted organs. Further advances are needed. Immunosuppression and tolerance based on regulatory T cells provide an attractive alternative because of their ability to target these immunomodulatory functions specifically to the anti-allograft immune response.
